RAGE antagonism prevents post-traumatic trigeminal neuropathy

Oct. 30, 2025

A recent study published in the journal Biochemical Pharmacology has uncovered a promising new approach to prevent post-traumatic trigeminal neuropathy (PTTN) development by targeting the advanced glycation end-products receptor (RAGE).

BioWorld Science Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for Nov. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 13, 2025.

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld Science

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld Science

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...